Reprogramming cancer cells in endocrine-related tumors

Open issues

M. Tafani, G. A. Perrone, B. Pucci, A. Russo, M. Bizzarri, J. I. Mechanick, A. Carpi, M. A. Russo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Reprogramming technologies have been developed to revert somatic differentiated cells into pluripotent stem cells that can be differentiated into different lineages potentially useful in stem cell therapy. Reprogramming methods have been progressively refined to increase their efficiency, to obtain a cell population suitable for differentiation, and to eliminate viral plasmid which could be responsible for many unwanted side-effects when used in personalized medicine. All these methods are aimed to introduce into the cell genes or mRNAs encoding a set of four transcription factors (OCT-4, SOX-2, KLF-4 and c-MYC) or a set of three lincRNAs (large intragenic non-coding RNAs) acting downstream of the reprogramming transcription factors OCT-4, SOX-2 and NANOG. Translational clinical applications in human pathologies and in developmental, repair and cancer biology have been numerous. Cancer cells can be, at least in principle, reprogrammed into a normal phenotype. This is a recently raised issue, rapidly advancing in many human tumors, especially endocrine-related cancers, such as breast, prostate and ovarian ca. The present review aims to describe basic phenomena observed in reprogramming tumor cells and solid tumors and to discuss their meaning in human hormone-related cancers. We will also discuss the fact that some of the targeted transcription factors are "normally" activated in a number of physiological processes, such as morphogenesis, hypoxia and wound healing, suggesting an in vivo role of reprogramming for development and homeostasis. Finally, we will review concerns and warnings raised for in vivo reprogramming of human tumors and for the use of induced pluripotent stem cells (iPSCs) in human therapy.

Original languageEnglish
Pages (from-to)1146-1151
Number of pages6
JournalCurrent Medicinal Chemistry
Volume21
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Endocrine Cells
Tumors
Stem cells
Cells
Transcription Factors
SOXC Transcription Factors
Neoplasms
Untranslated RNA
Pathology
Medicine
Endocrine Gland Neoplasms
Plasmids
Repair
Physiological Phenomena
Genes
Induced Pluripotent Stem Cells
Hormones
Pluripotent Stem Cells
Precision Medicine
Messenger RNA

Keywords

  • Cellular and molecular rehabilitation
  • Endocrine-related cancer
  • HIF-1alpha
  • Hypoxia
  • IPSC
  • NFkB
  • OCT-4
  • Reprogramming cancer cells
  • SOX-2

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Reprogramming cancer cells in endocrine-related tumors : Open issues. / Tafani, M.; Perrone, G. A.; Pucci, B.; Russo, A.; Bizzarri, M.; Mechanick, J. I.; Carpi, A.; Russo, M. A.

In: Current Medicinal Chemistry, Vol. 21, No. 9, 2014, p. 1146-1151.

Research output: Contribution to journalArticle

Tafani, M, Perrone, GA, Pucci, B, Russo, A, Bizzarri, M, Mechanick, JI, Carpi, A & Russo, MA 2014, 'Reprogramming cancer cells in endocrine-related tumors: Open issues', Current Medicinal Chemistry, vol. 21, no. 9, pp. 1146-1151. https://doi.org/10.2174/0929867321666131129125624
Tafani, M. ; Perrone, G. A. ; Pucci, B. ; Russo, A. ; Bizzarri, M. ; Mechanick, J. I. ; Carpi, A. ; Russo, M. A. / Reprogramming cancer cells in endocrine-related tumors : Open issues. In: Current Medicinal Chemistry. 2014 ; Vol. 21, No. 9. pp. 1146-1151.
@article{371edaa8127b46f29f78853962d17946,
title = "Reprogramming cancer cells in endocrine-related tumors: Open issues",
abstract = "Reprogramming technologies have been developed to revert somatic differentiated cells into pluripotent stem cells that can be differentiated into different lineages potentially useful in stem cell therapy. Reprogramming methods have been progressively refined to increase their efficiency, to obtain a cell population suitable for differentiation, and to eliminate viral plasmid which could be responsible for many unwanted side-effects when used in personalized medicine. All these methods are aimed to introduce into the cell genes or mRNAs encoding a set of four transcription factors (OCT-4, SOX-2, KLF-4 and c-MYC) or a set of three lincRNAs (large intragenic non-coding RNAs) acting downstream of the reprogramming transcription factors OCT-4, SOX-2 and NANOG. Translational clinical applications in human pathologies and in developmental, repair and cancer biology have been numerous. Cancer cells can be, at least in principle, reprogrammed into a normal phenotype. This is a recently raised issue, rapidly advancing in many human tumors, especially endocrine-related cancers, such as breast, prostate and ovarian ca. The present review aims to describe basic phenomena observed in reprogramming tumor cells and solid tumors and to discuss their meaning in human hormone-related cancers. We will also discuss the fact that some of the targeted transcription factors are {"}normally{"} activated in a number of physiological processes, such as morphogenesis, hypoxia and wound healing, suggesting an in vivo role of reprogramming for development and homeostasis. Finally, we will review concerns and warnings raised for in vivo reprogramming of human tumors and for the use of induced pluripotent stem cells (iPSCs) in human therapy.",
keywords = "Cellular and molecular rehabilitation, Endocrine-related cancer, HIF-1alpha, Hypoxia, IPSC, NFkB, OCT-4, Reprogramming cancer cells, SOX-2",
author = "M. Tafani and Perrone, {G. A.} and B. Pucci and A. Russo and M. Bizzarri and Mechanick, {J. I.} and A. Carpi and Russo, {M. A.}",
year = "2014",
doi = "10.2174/0929867321666131129125624",
language = "English",
volume = "21",
pages = "1146--1151",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Reprogramming cancer cells in endocrine-related tumors

T2 - Open issues

AU - Tafani, M.

AU - Perrone, G. A.

AU - Pucci, B.

AU - Russo, A.

AU - Bizzarri, M.

AU - Mechanick, J. I.

AU - Carpi, A.

AU - Russo, M. A.

PY - 2014

Y1 - 2014

N2 - Reprogramming technologies have been developed to revert somatic differentiated cells into pluripotent stem cells that can be differentiated into different lineages potentially useful in stem cell therapy. Reprogramming methods have been progressively refined to increase their efficiency, to obtain a cell population suitable for differentiation, and to eliminate viral plasmid which could be responsible for many unwanted side-effects when used in personalized medicine. All these methods are aimed to introduce into the cell genes or mRNAs encoding a set of four transcription factors (OCT-4, SOX-2, KLF-4 and c-MYC) or a set of three lincRNAs (large intragenic non-coding RNAs) acting downstream of the reprogramming transcription factors OCT-4, SOX-2 and NANOG. Translational clinical applications in human pathologies and in developmental, repair and cancer biology have been numerous. Cancer cells can be, at least in principle, reprogrammed into a normal phenotype. This is a recently raised issue, rapidly advancing in many human tumors, especially endocrine-related cancers, such as breast, prostate and ovarian ca. The present review aims to describe basic phenomena observed in reprogramming tumor cells and solid tumors and to discuss their meaning in human hormone-related cancers. We will also discuss the fact that some of the targeted transcription factors are "normally" activated in a number of physiological processes, such as morphogenesis, hypoxia and wound healing, suggesting an in vivo role of reprogramming for development and homeostasis. Finally, we will review concerns and warnings raised for in vivo reprogramming of human tumors and for the use of induced pluripotent stem cells (iPSCs) in human therapy.

AB - Reprogramming technologies have been developed to revert somatic differentiated cells into pluripotent stem cells that can be differentiated into different lineages potentially useful in stem cell therapy. Reprogramming methods have been progressively refined to increase their efficiency, to obtain a cell population suitable for differentiation, and to eliminate viral plasmid which could be responsible for many unwanted side-effects when used in personalized medicine. All these methods are aimed to introduce into the cell genes or mRNAs encoding a set of four transcription factors (OCT-4, SOX-2, KLF-4 and c-MYC) or a set of three lincRNAs (large intragenic non-coding RNAs) acting downstream of the reprogramming transcription factors OCT-4, SOX-2 and NANOG. Translational clinical applications in human pathologies and in developmental, repair and cancer biology have been numerous. Cancer cells can be, at least in principle, reprogrammed into a normal phenotype. This is a recently raised issue, rapidly advancing in many human tumors, especially endocrine-related cancers, such as breast, prostate and ovarian ca. The present review aims to describe basic phenomena observed in reprogramming tumor cells and solid tumors and to discuss their meaning in human hormone-related cancers. We will also discuss the fact that some of the targeted transcription factors are "normally" activated in a number of physiological processes, such as morphogenesis, hypoxia and wound healing, suggesting an in vivo role of reprogramming for development and homeostasis. Finally, we will review concerns and warnings raised for in vivo reprogramming of human tumors and for the use of induced pluripotent stem cells (iPSCs) in human therapy.

KW - Cellular and molecular rehabilitation

KW - Endocrine-related cancer

KW - HIF-1alpha

KW - Hypoxia

KW - IPSC

KW - NFkB

KW - OCT-4

KW - Reprogramming cancer cells

KW - SOX-2

UR - http://www.scopus.com/inward/record.url?scp=84896330518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896330518&partnerID=8YFLogxK

U2 - 10.2174/0929867321666131129125624

DO - 10.2174/0929867321666131129125624

M3 - Article

VL - 21

SP - 1146

EP - 1151

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 9

ER -